Janus Kinase Inhibitor for Treatment of Axial Spondyloarthritis and Psoriatic Arthritis
Article Sidebar
Main Article Content
Abstract
Spondyloarthritis (SpA) เป็นกลุ่มโรคที่มีการอักเสบเรื้อรัง มีอาการแสดงทั้งอาการทางข้อและอาการนอกข้อ โรคกระดูกสันหลังอักเสบชนิดแกนเด่น (axial spondyloarthritis หรือ axSpA) และโรคข้ออักเสบสะเก็ดเงิน (psoriasis arthritis, PSA) เป็นโรคที่พบได้บ่อยในกลุ่มโรค SpA ในปัจจุบันมีทีมแพทย์ผู้เชี่ยวชาญแนะนำแนวทางการรักษาด้วยยา ประกอบด้วยยาต้านการอักเสบชนิดที่ไม่ใช่สเตียรอยด์ (NSAIDs) ยาต้านรูมาติกที่ปรับเปลี่ยนการดำเนินโรคดั้งเดิม (conventional DMARDs) ยาชีววัตถุ (biological DMARDs) รวมทั้งมีการศึกษายาใหม่ในกลุ่ม Janus kinase inhibitor (JAKi) ซึ่งเป็นยาที่ออกฤทธิ์พุ่งเป้ามาใช้ในการรักษาโรคกลุ่มนี้ โดยมีจุดมุ่งหมายให้การรักษามีประสิทธิภาพและปลอดภัยมากขึ้น อย่างไรก็ตามการศึกษายา JAKi ในการรักษาผู้ป่วยโรค axSpA และโรค PSA ยังมีไม่มากและเป็นการศึกษาระยะสั้น จำเป็นต้องมีการติดตามประสิทธิภาพของยาด้านการรักษาโรครวมถึงความปลอดภัยในระยะยาวต่อไป ควรพิจารณาเลือกใช้ยา JAKi ด้วยความระมัดระวังและให้เหมาะสมกับผู้ป่วยแต่ละราย
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
(ใส่ข้อความเดียวกันกับ ก๊อปปี้ไลน์ก็ได้)ดูตัวอย่างได้ที่หน้าบทความ---บทความนี้ตีพิมพ์เป็นลิขสิทธื์ของใคร...
References
Sharip A, Kunz J. Understanding the Pathogenesis of Spondyloarthritis. Biomolecules. 2020;10(10).
Healy PJ, Helliwell PS. Classification of the spondyloarthropathies. Curr Opin Rheumatol. 2005;17(4):395-9.
Sjef Van Der Linden MB, Lianne S. Gensler. Ankylosing Spondylitis and other Forms of Axial Spondyloarthritis. In: Gary S.Firestein RCB, Sherine E Gabriel, editor. Firestein&Kelley's Textbook of Rheumatology. 11 ed2021. p. 1319-41.
Zhu W, He X, Cheng K, Zhang L, Chen D, Wang X, et al. Ankylosing spondylitis: etiology, pathogenesis, and treatments. Bone Res. 2019;7:22.
de Koning A, Schoones JW, van der Heijde D, van Gaalen FA. Pathophysiology of axial spondyloarthritis: Consensus and controversies. Eur J Clin Invest. 2018;48(5):e12913.
van der Heijde D, Ramiro S, Landewe R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis. 2017;76(6):978-91.
Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-12.
Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2019;71(10):1599-613.
Reveille JD. The genetic basis of spondyloarthritis. Current Rheumatology Reports. 2004;6(2):117-25.
Fong KY. The genetics of spondyloarthropathies. Ann Acad Med Singap. 2000;29(3):370-5.
Smith JA, Marker-Hermann E, Colbert RA. Pathogenesis of ankylosing spondylitis: current concepts. Best Pract Res Clin Rheumatol. 2006;20(3):571-91.
Gooren LJ, Giltay EJ, van Schaardenburg D, Dijkmans BA. Gonadal and adrenal sex steroids in ankylosing spondylitis. Rheum Dis Clin North Am. 2000;26(4):969-87.
Cai G, Wang L, Fan D, Xin L, Liu L, Hu Y, et al. Vitamin D in ankylosing spondylitis: Review and meta-analysis. Clinica Chimica Acta. 2015;438:316-22.
KA S, A.Colbert R. Etiology and Pathogenesis of Spondyloarthritis. In: Gary S.Firestein RCB, Sherine E Gabriel, editor. Firestein & Kelley's Textbook of Rheumatology 1: Elsevier; 2020. p. 1307-18.
Taurog JD, Chhabra A, Colbert RA. Ankylosing Spondylitis and Axial Spondyloarthritis. N Engl J Med. 2016;374(26):2563-74.
Hammer RE, Maika SD, Richardson JA, Tang JP, Taurog JD. Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2m: an animal model of HLA-B27-associated human disorders. Cell. 1990;63(5):1099-112.
Sorrentino R, Böckmann RA, Fiorillo MT. HLA-B27 and antigen presentation: at the crossroads between immune defense and autoimmunity. Mol Immunol. 2014;57(1):22-7.
Noordenbos T, Yeremenko N, Gofita I, van de Sande M, Tak PP, Caňete JD, et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum. 2012;64(1):99-109.
Baeten D. Pathogenesis and pathophysiology of axial spondyloarthritis. In: Alan Silman JS, Michael Weinblatt, editor. Rheumatology. 1. 7th ed: Elsevier; 2018. p. 1009-14.
Nash P, Kerschbaumer A, Dorner T, Dougados M, Fleischmann RM, Geissler K, et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann Rheum Dis. 2021;80(1):71-87.
Akkoc N, Khan MA. JAK Inhibitors for Axial Spondyloarthritis: What does the Future Hold? Curr Rheumatol Rep. 2021;23(6):34.
Raychaudhuri SK, Raychaudhuri SP. Janus kinase/signal transducer and activator of transcription pathways in spondyloarthritis. Curr Opin Rheumatol. 2017;29(4):311-6.
Hammitzsch A, Lorenz G, Moog P. Impact of Janus Kinase Inhibition on the Treatment of Axial Spondyloarthropathies. Front Immunol. 2020;11:591176.
Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023;82(1):19-34.
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5-32.
Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706-19.
Coates LC, Soriano ER, Corp N, Bertheussen H, Callis Duffin K, Campanholo CB, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465-79.
Dowty ME, Lin J, Ryder TF, Wang W, Walker GS, Vaz A, et al. The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Tofacitinib, a Janus Kinase Inhibitor, in Humans. Drug Metabolism and Disposition. 2014;42(4):759-73.
Keeling S, Maksymowych WP. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials. Expert Rev Clin Immunol. 2021;17(7):701-15.
Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-39.
Wollenhaupt J, Lee EB, Curtis JR, Silverfield J, Terry K, Soma K, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89.
XELJANZ (Tofacitinib).EPAR-Product Information.European Medicines Agency [Internet]. Available from: https://www.ema.europa.eu/en/documents/product-information/xeljanz-epar-product information_en.pdf.
van der Heijde D, Deodhar A, Wei JC, Drescher E, Fleishaker D, Hendrikx T, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017;76(8):1340-7.
Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021.
Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F, et al. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis. N Engl J Med. 2017;377(16):1537-50.
Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, et al. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. N Engl J Med. 2017;377(16):1525-36.
Mohamed M-EF, Klünder B, Othman AA. Clinical Pharmacokinetics of Upadacitinib: Review of Data Relevant to the Rheumatoid Arthritis Indication. Clin Pharmacokinet. 2020;59(5):531-44.
Muensterman E, Engelhardt B, Gopalakrishnan S, Anderson JK, Mohamed MF. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials. Clin Transl Sci. 2022;15(1):267-78.
Duggan S, Keam SJ. Upadacitinib: First Approval. Drugs. 2019;79(16):1819-28.
van der Heijde D, Song I-H, Pangan AL, Deodhar A, van den Bosch F, Maksymowych WP, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. The Lancet. 2019;394(10214):2108-17.
McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021;384(13):1227-39.
Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020.
Dhillon S, Keam SJ. Filgotinib: First Approval. Drugs. 2020;80(18):1987-97.
Namour F, Anderson K, Nelson C, Tasset C. Filgotinib: A Clinical Pharmacology Review. Clin Pharmacokinet. 2022;61(6):819-32.
van der Heijde D, Baraliakos X, Gensler LS, Maksymowych WP, Tseluyko V, Nadashkevich O, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. The Lancet. 2018;392(10162):2378-87.
Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. The Lancet. 2018;392(10162):2367-77.
Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP, et al. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford). 2019;58(10):1755-66.
Olivera PA, Lasa JS, Bonovas S, Danese S, Peyrin-Biroulet L. Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis. Gastroenterology. 2020;158(6):1554-73 e12.
Iwamoto N, Sato S, Kurushima S, Michitsuji T, Nishihata S, Okamoto M, et al. Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis. Arthritis Res Ther. 2021;23(1):197.
Nash P, Coates LC, Kivitz AJ, Mease PJ, Gladman DD, Covarrubias-Cobos JA, et al. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. Rheumatol Ther. 2020;7(3):553-80.
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, Van Assen S, Bijl M, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Annals of the rheumatic diseases. 2020;79(1):39-52.
Venerito V, Stefanizzi P, Cantarini L, Lavista M, Galeone MG, Di Lorenzo A, et al. Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study. Int J Mol Sci. 2023;24(8).
Esteban-Vazquez A, Steiner M, Castaneda E, Andreu-Vazquez C, Thiussard IJ, Somodevilla A, et al. The Real-World Study of Immunogenicity and Safety of the Adjuvant Recombinant Vaccine against Varicella Zoster Virus in Patients with Immune-Mediated Inflammatory Diseases Treated with Janus Kinase Inhibitors. Vaccines (Basel). 2023;11(10).
Pons-Bas A, Rosas J, Pons-Canet L, Senabre-Gallego JM, Santos Soler G, Bernal JA, et al. AB1774-HPR SAFETY OF THE RECOMBINANT HERPES ZOSTER VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH JAKI DRUGS. Annals of the Rheumatic Diseases. 2023;82(Suppl 1):2121-.
Curtis JR, Lee EB, Kaplan IV, Kwok K, Geier J, Benda B, et al. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme. Ann Rheum Dis. 2016;75(5):831-41.
Solipuram V, Mohan A, Patel R, Ni R. Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Auto Immun Highlights. 2021;12(1):8.
Winthrop KL, Cohen SB. Oral surveillance and JAK inhibitor safety: the theory of relativity. Nat Rev Rheumatol. 2022.
Kremer JM, Bingham CO, 3rd, Cappelli LC, Greenberg JD, Madsen AM, Geier J, et al. Postapproval Comparative Safety Study of Tofacitinib and Biological Disease-Modifying Antirheumatic Drugs: 5-Year Results from a United States-Based Rheumatoid Arthritis Registry. ACR Open Rheumatol. 2021;3(3):173-84.